Myriad Genetics ((MYGN)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Myriad Genetics (MYGN) is collaborating on a clinical study titled SHARON: Study of Metastatic Cancers in Patients With a Defect in a Homologous Recombination Gene Using Autologous Stems Cells and Potentiated Redox Cycling to Overcome Drug Resistance to Nitrogen Mustard Derivatives. The study aims to evaluate the safety of a novel treatment for metastatic cancer in patients with BRCA1, BRCA2, or PALB2 mutations, which could significantly impact treatment options for these genetic conditions.
The intervention being tested is a combination of chemotherapy drugs—Melphalan, BCNU, Vitamin B12b, Vitamin C, and Ethanol—administered intravenously, followed by an infusion of the patient’s own stem cells. This approach seeks to overcome drug resistance in cancer treatment.
This phase 1 study employs a single-group, non-randomized design without masking, focusing on treatment as its primary purpose. It aims to determine the safety and potential efficacy of the treatment in a controlled setting.
The study began on October 30, 2019, with its latest update submitted on August 18, 2025. These dates are crucial for tracking the study’s progress and ensuring transparency in its development.
The ongoing study could influence Myriad Genetics’ stock performance by showcasing its commitment to innovative cancer treatments. Positive results may boost investor confidence, especially in the competitive field of genetic-based cancer therapies.
The study is currently recruiting, and further details can be accessed on the ClinicalTrials portal.